All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
Bookmark this article
FMS-like tyrosine kinase 3 (FLT3) is a commonly occurring gene mutation in approximately 30% of patients with acute myeloid leukemia (AML). Midostaurin is a multikinase, first-generation, type 2 inhibitor that directly inhibits FLT3 signaling and induces apoptosis in FLT3-mutated leukemic cells. The pivotal RATIFY trial, previously reported by the AML Hub, demonstrated that midostaurin significantly reduced mortality in adult patients aged <60 years with newly diagnosed FLT3-mutated AML.1
The AML Hub is pleased to present a visual abstract summarizing the efficacy and safety outcomes from a phase IIIb trial (NCT03379727) of midostaurin plus idarubicin or daunorubicin in young (≤60 years) and older (≥60 years) patients with newly diagnosed FLT3-mutated AML.1
To download this visual abstract, click below.Download here
2022 ELN recommendations for the management of AML in adults
A summary of the updated guidelines for the management of AML, from the same publication in Blood, by Döhner et al. on behalf of the ELN.
Triplet combination of HMA, FLT3 inhibitors, and venetoclax in FLT3-mutated newly diagnosed AML
This study suggests that in older/unfit adult patients with newly diagnosed AML the triplet combination of HMA, FLT3 inhibitor, and venetoclax is...
Subscribe to get the best content related to AML delivered to your inbox